This Stock Just Became the Dividend Growth Bargain of 2026

Dividend grower UnitedHealth is finally a buy after CMS surprised with new, higher Medicare Advantage rates. Down 53% with a 3.1% yield, the April 21 earnings report should be the inflection point investors have waited for.

Healthcare investors have watched managed-care giants absorb one regulatory and operational hit after another over the past 18 months. Cyberattack costs, membership exits, and razor-thin Medicare proposals weighed on the sector. Yet, the Centers for Medicare & Medicaid Services just delivered a surprise lift: a finalized 2.48% net average increase for 2027 Medicare Advantage payments, equaling more than $13 billion in extra funding.

What does that mean for UnitedHealth Group (UNH), the largest player in the space? It now trades with a clear runway to prove its reset worked. Shares are down 53% from their 52-week high, and its April 21 earnings report offers the first clean look at the post-restructuring business. Here’s why the data now supports adding this name to dividend portfolios.

Dividend Dependability Through Turbulence
UNH has delivered dividends for 24 years and raised the payout for 16 consecutive years. That streak held firm even through 2025’s roughest stretch. Full-year operating income dropped 41%, the medical care ratio climbed 340 basis points to 88.9%, and the company absorbed a $2.88 billion pre-tax charge in Q4 that included $799 million in final cyberattack remediation.

Despite all that, the board kept the dividend intact and still managed a 5.24% increase for the current year. The annual payout now totals $8.84 per share, producing a 3.13% yield. In plain English, that’s cash flow reliability most retail investors find enviable in a $500 billion-plus company.

Medicare Advantage Tailwind Fuels Recovery
The CMS rate hike is far above the 0.09% proposal floated in January. When risk-score trends are layered in, the effective boost approaches 4.98%. For UnitedHealth, which generates meaningful revenue from these plans, the extra $13 billion across the industry removes a major earnings drag and supports the 2026 medical care ratio guidance of 88.8%.

Management also plans an orderly exit from 2.3 million to 2.8 million unprofitable members, trimming total UNH enrollment to 46.9 million to 47.5 million. That deliberate pruning, paired with the new rates, sets up Optum Health for its targeted 9% operating-earnings growth this year.

The Earnings Catalyst and Valuation Edge
The insurer’s full-year guidance projects adjusted earnings per share above $17.75 – up from $16.35 last year – and revenue above $439 billion. The April 21 print marks new CEO Stephen Hemsley’s first quarterly test without restructuring noise or lingering cyber costs.

Wall Street’s consensus price target stands at $357.81, implying roughly 27% upside from its current price. That’s a meaningful gap for a company that has compounded dividends at a mid-teens pace over the past decade while peers like Humana (HUM) and CVS (CVS) grappled with similar rate uncertainty.

Key Takeaway
UnitedHealth Group has proven dividend durability through its toughest stretch in years and just received a $13 billion federal tailwind that analysts didn’t fully price in. At a 3.13% yield and 27% implied upside to consensus targets, the stock finally qualifies as a buy for investors who want growth plus income. Place your order before April 21 if you want to own the rebound from the ground floor.

— Rich Duprey

Source: Money Morning